Frontiers in Oncology: The SCL/NJH Oncology Symposium 2018
Expanding the Reach of Precision Medicine in Lung Cancer
Friday, May 18, 2018
- 5:30 p.m., Reception: Sterne Elder Conference Room at Saint Joseph Hospital
- 7:00 - 8:00 p.m., Lecture: Rainer Auditorium (no food or drinks are allowed)
- Registration is free and includes the reception and the lecture.
Saint Joseph Hospital
1375 E. 19th Ave.
Denver, CO 80218
SJH Campus Map (PDF)
Please enter through the Main Entrance to the hospital.
Complimentary valet parking service is available until 9:00 p.m.
Who Should Attend:
Denver-Based Oncology Medical Professionals
Recognize the broad diversity of genomic changes within non-small cell lung cancers that can be effectively targeted within clinical trials
Incorporate ongoing findings from clinical trials of patients with specific genomic changes into the evaluation and treatment of patients with non-small cell lung cancer
Assess the outcome of patients with genomic changes that are successfully targeted both within and outside of clinical trials
Bruce E. Johnson, MD (bio)
Chief Clinical Research Officer
Professor of Medicine, Harvard Medical School
Dana-Farber/Harvard Cancer Center Lung Cancer Program
Alan M. Miller, MD, PhD (bio)
Chief Medical Director of Oncology
Associate Chief Medical Director of Clinical Research
Cancer Centers of Colorado
Jeffrey Kern, MD (bio)
Chief, Division of Oncology, Cancer Center
Director, Lung Cancer Center
Vice Chair, Finance
Professor of Medicine
National Jewish Health
Please register here. Registration is free and includes the reception and the lecture. For questions, please contact the Office of Professional Education at 303.398.1000 or firstname.lastname@example.org.
Physician Accreditation & Designation Statement
National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
National Jewish Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.